Motohiro Tamiya

3.5k total citations
163 papers, 1.9k citations indexed

About

Motohiro Tamiya is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Motohiro Tamiya has authored 163 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Pulmonary and Respiratory Medicine, 115 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in Motohiro Tamiya's work include Lung Cancer Treatments and Mutations (109 papers), Lung Cancer Research Studies (52 papers) and Lung Cancer Diagnosis and Treatment (41 papers). Motohiro Tamiya is often cited by papers focused on Lung Cancer Treatments and Mutations (109 papers), Lung Cancer Research Studies (52 papers) and Lung Cancer Diagnosis and Treatment (41 papers). Motohiro Tamiya collaborates with scholars based in Japan, United States and United Kingdom. Motohiro Tamiya's co-authors include Tomonori Hirashima, Takako Inoue, Takayuki Shiroyama, Akihiro Tamiya, Fumio Imamura, Norio Okamoto, Toru Kumagai, Shinji Atagi, Kazumi Nishino and Hidekazu Suzuki and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Motohiro Tamiya

148 papers receiving 1.8k citations

Peers

Motohiro Tamiya

PRM

ONCOL

SURGE

Myung‐Ju Ahn South Korea

Shintaro Kanda Japan

Héctor Soto Parrà Italy

Gongyan Chen China

Amelia Insa Spain

Robin Cornelissen Netherlands

Miloš Pešek Czechia

Diego Signorelli Italy

Miso Kim South Korea

Cristian Lolli Italy

Myung‐Ju Ahn South Korea

Motohiro Tamiya

990 ×0.8

PRM

792 ×0.7

ONCOL

250 ×0.8

139 ×0.7

175 ×1.2

SURGE

Citations per year, relative to Motohiro Tamiya Motohiro Tamiya (= 1×) peers Myung‐Ju Ahn

Countries citing papers authored by Motohiro Tamiya

Since Specialization

Citations

This map shows the geographic impact of Motohiro Tamiya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Motohiro Tamiya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Motohiro Tamiya more than expected).

Fields of papers citing papers by Motohiro Tamiya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Motohiro Tamiya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Motohiro Tamiya. The network helps show where Motohiro Tamiya may publish in the future.

Co-authorship network of co-authors of Motohiro Tamiya

This figure shows the co-authorship network connecting the top 25 collaborators of Motohiro Tamiya. A scholar is included among the top collaborators of Motohiro Tamiya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Motohiro Tamiya. Motohiro Tamiya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shitara, Kohei, Motohiro Tamiya, Kyoichi Okishio, et al.. (2025). Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study. Cancer Research Communications. 5(10). 1809–1820.

Nishinakamura, Hitomi, Takuma Irie, Takeo Naito, et al.. (2025). Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade. Science Translational Medicine. 17(785). eadk3160–eadk3160. 8 indexed citations

Miyamoto, Shimpei, Hanako Kuhara, Takayuki Shiroyama, et al.. (2025). Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan. Thoracic Cancer. 16(6). e70047–e70047. 1 indexed citations

Fujimoto, Daichi, Ryota Shibaki, Keiichi Kimura, et al.. (2025). Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning. Lung Cancer. 199. 108079–108079. 1 indexed citations

Kunimasa, Kei, Motohiro Tamiya, Takako Inoue, et al.. (2024). Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer. Lung Cancer. 189. 107498–107498. 4 indexed citations

Nakabori, Tasuku, Kei Kunimasa, Kaori Mukai, et al.. (2024). Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants. Cancer Medicine. 13(12). e7430–e7430. 1 indexed citations

Nishio, Makoto, Shuji Murakami, Hisato Kawakami, et al.. (2024). Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. Cancer Research Communications. 4(1). 226–235. 2 indexed citations

Watanabe, Kageaki, Keita Sasaki, Ryunosuke Machida, et al.. (2024). High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group). Japanese Journal of Clinical Oncology. 54(10). 1084–1092. 3 indexed citations

Inoue, Takako, Takashi Akazawa, Kei Kunimasa, et al.. (2024). Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG‐E8. Cancer Science. 115(4). 1114–1128. 3 indexed citations

10.

Matsumoto, Kinnosuke, Yuji Yamamoto, Takayuki Shiroyama, et al.. (2024). Risk Stratification According to Baseline and Early Change in Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Treated with Chemoimmunotherapy: A Multicenter Real-World Study. Targeted Oncology. 19(5). 757–767.

11.

Kunimasa, Kei, Shingo Matsumoto, Takahisa Kawamura, et al.. (2023). Clinical application of the AMOY 9-in-1 panel to lung cancer patients. Lung Cancer. 179. 107190–107190. 20 indexed citations

12.

Nakahara, Yoshiro, Terufumi Kato, Toshihiro Misumi, et al.. (2023). LBA70 OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833). Annals of Oncology. 34. S1313–S1313. 9 indexed citations

13.

Tsukita, Yoko, Takaya Yamamoto, Hiroshi Mayahara, et al.. (2021). Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study. Radiotherapy and Oncology. 160. 266–272. 30 indexed citations

14.

Kunimasa, Kei, Toru Oka, Makiko Oboshi, et al.. (2020). Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib. JACC CardioOncology. 2(1). 1–10. 58 indexed citations

15.

Kunimasa, Kei, Toru Oka, Satoshi Hara, et al.. (2020). Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction. Lung Cancer. 153. 186–192. 24 indexed citations

16.

Kumagai, Toru, Yasuhiko Tomita, Shin‐ichi Nakatsuka, et al.. (2018). HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1. Thoracic Cancer. 9(4). 466–471. 9 indexed citations

17.

Hirashima, Tomonori, Hidekazu Suzuki, Norio Okamoto, et al.. (2014). Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis. Oncology Letters. 8(1). 327–334. 6 indexed citations

18.

Asami, Kazuhiro, Masaaki Kawahara, Tomonori Hirashima, et al.. (2014). Prospective phase II study of cisplatin plus pemetrexed with maintenance of pemetrexed for advanced non‐squamous cell non‐small cell lung cancer in Japan. Thoracic Cancer. 5(4). 289–296. 2 indexed citations

19.

Tamiya, Akihiro, Motohiro Tamiya, Takayuki Shiroyama, et al.. (2012). Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Annals of Oncology. 24(4). 980–985. 22 indexed citations

20.

Tamiya, Motohiro, Shinya Tokunaga, Hidekazu Suzuki, et al.. (2012). Prospective Study of Urinary and Serum Cross-Linked N-Telopeptide of Type I Collagen (NTx) for Diagnosis of Bone Metastasis in Patients With Lung Cancer. Clinical Lung Cancer. 14(4). 364–369. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact